Portfolio companies news

01 August 2016

Clearside Biomedical, Inc. Announces Promotion of Glenn Noronha, Ph.D. to Chief Scientific Officer and Jennifer M. Kissner, Ph.D. to Vice President, Clinical Development

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that  Glenn Noronha , Ph.D., has been promoted to Chief Scientific Officer and  Jennifer M. Kissner , Ph.D., has been promoted to Vice President, Clinical Development. Both Drs. Noronha and Kissner will assume their roles immediately and will report to  Daniel H. White , CEO and President of  Clearside Biomedical .

27 July 2016

Syndax Appoints Leading Experts to Scientific Advisory Board (SAB)

Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with UCB for UCB6352, an IND-ready anti-CSF-1R monoclonal antibody, which is expected to begin clinical trials in 2016.

27 July 2016

NovaMedica Strengthens its Team

Russian pharmaceutical company NovaMedica announces strengthening of its team. Elena Ilyina formerly holding one of the key positions in Sun Pharma (Ranbaxy) Russia is appointed as Vice President, Business Development.

26 July 2016

Clearside Biomedical, Inc. Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reports additional top-line data from its Phase 2 clinical trial (TANZANITE). 78% of Patients Required No Additional Treatment in the Trial Arm with Concomitant Suprachoroidally Administered Zuprata™ and Intravitreally Administered Eylea®.

25 July 2016

ReVision Optics Appoints Frank Shields Vice President of Sales Worldwide

ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces the appointment of Frank Shields to the newly created position of Vice President of Sales Worldwide effective immediately. Mr. Shields brings more than 25 years of experience in surgical sales at leading ophthalmic companies and has been instrumental in the launch of several leading ophthalmic lens products. He will be responsible for leading the commercialization of the Raindrop Near Vision Inlay in the U.S. and expanding international sales.

25 July 2016

Tobira’s Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH

Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced results from CENTAUR, its Phase 2b clinical trial evaluating the efficacy and safety of cenicriviroc (CVC) for the treatment of NASH in 289 adults with liver fibrosis. 

07 July 2016

Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test to Predict Treatment Response in Metastatic Prostate Cancer

Genomic Health, Inc. (GHDX) and Epic Sciences, Inc. today announced an exclusive agreement to commercialize Epic Sciences' novel AR-V7 liquid biopsy test in the United States through Genomic Health's world-class commercial channel. The blood-based test detects the V7 variant of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells (CTC) – information that can help guide treatment selection in patients with metastatic castration-resistant prostate cancer (mCRPC).

06 July 2016

Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB's Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program

Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with UCB for UCB6352, an IND-ready anti-CSF-1R monoclonal antibody, which is expected to begin clinical trials in 2016.

29 June 2016

ReVision Optics Receives FDA Approval for the Raindrop® Near Vision Inlay

 ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces receipt of U.S. Food and Drug Administration (FDA) approval for the Raindrop® Near Vision Inlay, a novel corneal inlay for the surgical correction of presbyopia. The Raindrop Near Vision Inlay is indicated to improve near vision by reshaping the anterior curvature of the cornea in presbyopic patients who have emmetropic refractions (+1.00 D to -0.50 D).

28 June 2016

Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced top-line data from a Phase 2 exploratory, investigator-sponsored study to evaluate the safety, tolerability and efficacy of ganaxolone for the treatment of anxiety and attention in children with Fragile X Syndrome (FXS). The investigator selected Clinical Global Impression of Improvement (CGI-I), which is a broad scale to assess the overall improvement  across the entire Fragile X Syndrome, as the primary endpoint of the study.